“Never” is a strong word. I can imagine selling some or all of just about any stock I own — perhaps because I suddenly need a lot of money to pay medical bills, or because a stock simply seems wildly overvalued and I’ve found a wildly undervalued one in which I have greater confidence.
Still, there are many stocks I own that I plan to own for perhaps two more decades — well into my retirement. Some of them I’ve already owned for a decade or two. Here are three examples — stocks I have no intention of selling anytime soon — because they’ve performed well for me and I expect more good things from them.
Costco (NASDAQ: COST) is a familiar name to most Americans. It’s familiar to plenty of people abroad, as well, as it recently boasted a total of 820 stores, only 568 of which are in the U.S.; other locations include Canada, Mexico, Japan, the United Kingdom, and South Korea. (Here’s a promising little detail: One of its stores is in China.)
While many investors may have been drooling over performances from the likes of Amazon.com or Microsoft, megaretailer Costco has been relatively quietly growing at a rapid clip. Its stock has grown in value more than sixfold over the past decade, without even counting dividends — that’s an average annual gain of more than 20%. It’s now the world’s third-largest retailer.
People are also reading…
In fiscal 2021, Costco’s revenue jumped 17% to nearly $200 billion, while earnings per share popped by 25%. Not bad for a behemoth in the exciting world of…discount retail. The company serves its three main constituents — customers, workers, and shareholders — very well: It caps markups on most items at around 14%, pays staffers above-average wages (which tends to keep them around longer), and rewards shareholders with stock-price appreciation and even a dividend. That dividend recently yielded just 0.63%, but the company has occasionally issued a special dividend, such as a $10-per-share one in 2020.
2. Intuitive Surgical
Intuitive Surgical (NASDAQ: ISRG) is not widely known, but it, too, has grown into a behemoth in its realm of robot-assisted surgeries. Its stock has grown more than sevenfold over the past decade, and the company recently sported a market value near $130 billion.
The company’s recent third-quarter earnings report featured impressive numbers, such as a 72% year-over-year increase in da Vinci surgical systems shipped, and an 11% increase in …….